Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298542 | 1.00 | NR1I2 (0.38) | NR1I2PTGS1ADRA1ALMNABLM | |
| SCHEMBL9298533 | 1.00 | NR1I2 (0.38) | NR1I2PTGS1ADRA1ALMNABLM | |
| SCHEMBL59076 | 1.00 | NR1I2 (0.38) | NR1I2PTGS1ADRA1ALMNABLM | |
| SCHEMBL9298092 | 1.00 | NR1I2 (0.38) | NR1I2PTGS1ADRA1ALMNABLM | |
| SCHEMBL9297121 | 1.00 | NR1I2 (0.38) | NR1I2PTGS1ADRA1ALMNABLM | |
| SCHEMBL9488170 | 0.81 | SLC7A5 (0.38) | SLC7A5 | |
| SCHEMBL18165403 | 0.81 | SLC1A2 (0.30) | — | |
| SCHEMBL30085758 | 0.81 | — | — | |
| SCHEMBL7052027 | 0.81 | SLC7A5 (0.38) | SLC7A5 | |
| SCHEMBL150490 | 0.81 | SLC7A5 (0.38) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-09-14 | — | — | US | claimed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | claimed |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-06-15 | — | — | US | claimed |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | claimed |
| EP-1049486-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 2000-11-08 | — | — | EP | claimed |
| US-5981488-A | POLYPEPTIDE; ANTIDIABETIC AGENT | ELI LILLLY AND COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| US-5977071-A | COMPLEXES; ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| WO-1999029336-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| EP-0869135-A1 | Glucagon-like peptide-1 analogs | ELI LILLY AND COMPANY (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0733644-A1 | Glucagon-like insulinotropic complexes, compositions and methods | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| US-5371234-A | Ion specific chelating agents derived from β-hydroxyhistidine, 4-(1-hydroxy-1-alkyl)imidazole and derivatives thereof | THE UNITES STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF COMMERCE (US) | 1994-12-06 | — | — | US | claimed |
| US-RE30413-E | ANTIBIOTICS; ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-10-07 | — | — | US | claimed |
| US-4051237-A | FROM STREPTOALLOTEICHUS HINDUSTANUS | BRISTOL-MYERS COMPANY (US) | 1977-09-27 | — | — | US | claimed |
| US-3932374-A | ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117947-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | NR1I2 3689/4885PTGS1 2380/4885ADRA1A 1896/4885 |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | NR1I2 3710/4885PTGS1 2313/4885ADRA1A 1943/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | NR1I2 648/4885PTGS1 142/4885ADRA1A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.